Pharma BD Deal Intelligence

Gilead Sciences, Inc. (via Kite Pharma) / Cell Design Labs, Inc.

2017 · Acquisition/Merger · $567M · Complete

Gilead/Kite agreed to acquire Cell Design Labs, a UCSF spinout developing synthetic biology platforms (synNotch and Throttle) for next-generation engineered cell therapies. Total deal value up to $567M, including $175M for the ~87.6% Cell Design Labs equity Kite did not already own plus up to $322M in development milestones (~$567M aggregate). The deal expanded Kite's CAR-T platform technology toolkit.

Did it work? Outcome assessment

Assessment window: 5yr post-close.

Key facts

• Announced Dec 07, 2017
• Closed Dec 12, 2017
• Deal value $567M
• Deal type Acquisition/Merger
• Therapeutic area Oncology (next-generation cellular therapy)
• Indications Oncology (next-generation cellular therapy)
• Key assets synNotch and Throttle T-cell engineering platforms
• Mechanism Synthetic biology platforms for engineered T-cell receptors and conditional T-cell activation

← Browse all deals  ·  How we score deals